Importance: Sleep disturbances are common during and after the menopause transition, with potential effects on morbidity and quality of life; however, they may be underdiagnosed and undertreated. Objective: We carried out a systematic literature review to investigate the prevalence and impact of sleep disturbances associated with menopause on women’s health-related quality of life across the stages of menopause. Evidence review: Searches were conducted in PubMed and Excerpta Medica Database to identify articles published between 2013 and 2023 containing evidence for the impact of sleep quality on health-related quality of life and the epidemiology of sleep disturbances in women in menopause. Findings: In total, 29 publications focusing on epidemiological outcomes of sleep disturbances and 28 studies focusing on the impact of sleep quality on health-related quality of life were identified. Overall, these studies confirmed the high prevalence of sleep disturbances in postmenopausal women. Risk factors for sleep disturbances included menopausal status, depression, vasomotor symptoms, high glycemic index diets, and age. Notably, sleep disturbances were identified even in the absence of vasomotor symptoms. Sleep disturbances were significantly associated with impaired menopause-specific and general health-related quality of life, including depression, anxiety, and musculoskeletal pain. Sleep disturbances were also associated with reduced work productivity and the ability to perform daily activities. Conclusions and relevance: Healthy sleep is important at all life stages, including during menopause. Our review indicates that sleep disturbances are highly prevalent during postmenopausal years, even among women without vasomotor symptoms, and can severely impact women’s well-being and quality of life. This study highlights the importance of promoting increased awareness and developing tailored treatment strategies for sleep disturbances in midlife and beyond.

The CAnadian Network for Psychedelic-Assisted Cancer Therapy (CAN-PACT) was launched in 2025 to address urgent gaps in supportive care for Canadians with cancer experiencing demoralization syndrome (loss of meaning, dysphoria, disheartenment, helplessness, a sense of failure) and related psychosocial distress. CAN-PACT has six major objectives: (1) to develop a national interdisciplinary research and practice network; (2) to set research priorities through structured stakeholder engagement; (3) to develop and provide PAT training and education for clinicians, researchers, and patients; (4) to pilot test the feasibility of intervention and assessment procedures; (5) to conduct a multi-center, randomized controlled trial of PAT for people with advanced cancer; and (6) to inform and influence healthcare policy on PAT in Canada. We discuss the background and need for PAT in cancer, describe challenges currently limiting its use, and outline CAN-PACT’s strategy for building capacity, generating Canadian evidence, and preparing the oncology healthcare environment for potential implementation. This manuscript presents a summary overview of CAN-PACT as a multi-objective research program; detailed protocols for each discrete study component will be published separately as the research program progresses. Through environmental scans, national engagement, targeted training, rigorous research, and ongoing collaboration with policymakers, CAN-PACT aims to enable equitable access to safe, evidence-based PAT for people with advanced cancer in Canada’s publicly funded cancer centers.

Elinzanetant, a dual neurokinin-1/-3 receptor antagonist, is approved for the treatment of moderate-to-severe vasomotor symptoms. The double-blind, randomized, placebo-controlled Phase III OASIS-1-4 studies evaluated elinzanetant's efficacy and safety in diverse populations of women, including those with vasomotor symptoms associated with natural or surgical menopause (OASIS-1, -2, and -3) and caused by endocrine therapy for breast cancer (OASIS-4). Results were similar across all trials for the respective primary and key secondary endpoints (included in the statistical testing hierarchy). Significant reductions vs. placebo in the frequency of vasomotor symptoms appeared from as early as week 1 in OASIS-1 and -2 (analyzed descriptively in OASIS-3 and -4), and at week 4 in OASIS-1, -2, and -4 (analyzed descriptively in OASIS-3). By week 12, all studies showed significant reductions vs. placebo, with benefits maintained for up to 50 weeks. In OASIS-1 and -2, the severity of vasomotor symptoms significantly decreased vs. placebo at weeks 4 and 12 (analyzed descriptively in OASIS-3 and -4). Elinzanetant treatment improved sleep disturbance, assessed by the Patient-Reported Outcomes Measurement Information System Sleep Disturbance Short Form 8b total T-score, and menopause-related quality of life, measured as total score on the Menopause-specific Quality of Life questionnaire, across all four trials as early as week 1. Significant reductions vs. placebo were seen at week 12 in OASIS-1, -2, and -4 (key secondary endpoints; analyzed descriptively in OASIS-3 as a secondary endpoint). Elinzanetant was generally well tolerated with consistent efficacy across all OASIS trials in diverse populations of women experiencing vasomotor symptoms.